Inozyme Pharma Total Debt vs. Book Value Per Share
| INZY Stock | USD 3.03 0.05 1.68% |
For Inozyme Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inozyme Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inozyme Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inozyme Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inozyme Pharma over time as well as its relative position and ranking within its peers.
Inozyme |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme Pharma. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Return On Assets (0.36) | Return On Equity (0.79) |
The market value of Inozyme Pharma is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inozyme Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme Pharma's market value can be influenced by many factors that don't directly affect Inozyme Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inozyme Pharma Book Value Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Inozyme Pharma's current stock value. Our valuation model uses many indicators to compare Inozyme Pharma value to that of its competitors to determine the firm's financial worth. Inozyme Pharma is rated second overall in total debt category among its peers. It is rated below average in book value per share category among its peers . The ratio of Total Debt to Book Value Per Share for Inozyme Pharma is about 36,117,829 . At this time, Inozyme Pharma's Book Value Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inozyme Pharma's earnings, one of the primary drivers of an investment's value.Inozyme Total Debt vs. Competition
Inozyme Pharma is rated second overall in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 175.35 Million. Inozyme Pharma totals roughly 46.59 Million in total debt claiming about 27% of equities under Health Care industry.
Inozyme Book Value Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Inozyme Pharma |
| = | 46.59 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Inozyme Pharma |
| = | 1.29 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Inozyme Book Value Per Share Comparison
Inozyme Pharma is currently under evaluation in book value per share category among its peers.
Inozyme Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Inozyme Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Inozyme Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Inozyme Pharma's change in net profit over the period of time. It can combine multiple indicators of Inozyme Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 41 K | 43 K | |
| Net Interest Income | 4.1 M | 4.3 M | |
| Interest Income | 4.1 M | 4.3 M | |
| Operating Income | -75.6 M | -79.4 M | |
| Net Loss | -68.2 M | -71.6 M | |
| Income Before Tax | -71.2 M | -74.7 M | |
| Total Other Income Expense Net | 4.5 M | 4.7 M | |
| Net Loss | -60.4 M | -63.4 M | |
| Net Loss | -71.2 M | -74.7 M | |
| Income Tax Expense | -1.5 M | -1.4 M | |
| Non Operating Income Net Other | 1.6 M | 1.7 M | |
| Change To Netincome | 8.8 M | 7 M | |
| Net Loss | (1.37) | (1.44) | |
| Income Quality | 0.99 | 1.03 | |
| Net Income Per E B T | 0.88 | 0.78 |
Inozyme Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Inozyme Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Inozyme Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Inozyme Pharma's important profitability drivers and their relationship over time.
Use Inozyme Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inozyme Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will appreciate offsetting losses from the drop in the long position's value.Inozyme Pharma Pair Trading
Inozyme Pharma Pair Trading Analysis
The ability to find closely correlated positions to Inozyme Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inozyme Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inozyme Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inozyme Pharma to buy it.
The correlation of Inozyme Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inozyme Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inozyme Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inozyme Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Inozyme Pharma position
In addition to having Inozyme Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run IT Thematic Idea Now
IT
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.